JP2002500202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002500202A5 JP2002500202A5 JP2000527281A JP2000527281A JP2002500202A5 JP 2002500202 A5 JP2002500202 A5 JP 2002500202A5 JP 2000527281 A JP2000527281 A JP 2000527281A JP 2000527281 A JP2000527281 A JP 2000527281A JP 2002500202 A5 JP2002500202 A5 JP 2002500202A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- rpe
- site
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 description 41
- 239000000203 mixture Substances 0.000 description 37
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 27
- 230000001225 therapeutic effect Effects 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 6
- 239000000790 retinal pigment Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US241398A | 1998-01-02 | 1998-01-02 | |
| US09/002,413 | 1998-01-02 | ||
| PCT/US1998/027730 WO1999034834A1 (en) | 1998-01-02 | 1998-12-31 | Use of pigmented retinal epithelial cells for creation of an immune privilege site |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002500202A JP2002500202A (ja) | 2002-01-08 |
| JP2002500202A5 true JP2002500202A5 (enExample) | 2006-01-05 |
Family
ID=21700636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000527281A Pending JP2002500202A (ja) | 1998-01-02 | 1998-12-31 | 免疫優位部位の生成のための色素性網膜上皮細胞の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060147437A1 (enExample) |
| EP (1) | EP1044024A1 (enExample) |
| JP (1) | JP2002500202A (enExample) |
| KR (1) | KR20010033834A (enExample) |
| AU (1) | AU759273B2 (enExample) |
| CA (1) | CA2317115A1 (enExample) |
| NZ (1) | NZ505459A (enExample) |
| WO (1) | WO1999034834A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115256B1 (en) | 1999-04-09 | 2006-10-03 | Titan Pharmaceuticals, Inc. | Methods of treating schizophrenia |
| JP2002281964A (ja) * | 2000-12-26 | 2002-10-02 | Sanyo Chem Ind Ltd | 細胞生産方法 |
| EP1362096B1 (de) * | 2001-02-21 | 2009-08-19 | CEVEC Pharmaceuticals GmbH | Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung |
| DE10108412B4 (de) * | 2001-02-21 | 2006-03-09 | Cevec Pharmaceuticals Gmbh | Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung |
| AU2002344959A1 (en) * | 2002-05-03 | 2003-11-17 | Nikolai Rainov | Use of fasl for the treatment of neurodegenerative diseases |
| US7312025B2 (en) | 2002-07-12 | 2007-12-25 | University Of Washington | Methods and systems for extended in vitro culture of neuronal cells |
| US20040156878A1 (en) * | 2003-02-11 | 2004-08-12 | Alireza Rezania | Implantable medical device seeded with mammalian cells and methods of treatment |
| US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
| SG188122A1 (en) * | 2004-01-23 | 2013-03-28 | Advanced Cell Tech Inc | Improved modalities for the treatment of degenerative diseases of the retina |
| ES2764473T3 (es) | 2007-10-12 | 2020-06-03 | Astellas Inst For Regenerative Medicine | Métodos mejorados para producir células RPE y composiciones de células RPE |
| WO2011063005A2 (en) | 2009-11-17 | 2011-05-26 | Advanced Cell Technology, Inc. | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
| CA2855941A1 (en) * | 2011-11-14 | 2013-05-23 | Advanced Cell Technology, Inc. | Pharmaceutical preparations of human rpe cells and uses thereof |
| WO2019222856A1 (en) | 2018-05-24 | 2019-11-28 | Nureva Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| EP3801462A4 (en) | 2018-05-24 | 2022-03-16 | Celanese EVA Performance Polymers LLC | Implantable device for sustained release of a macromolecular drug compound |
| WO2019226519A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| JP2024515220A (ja) | 2021-04-26 | 2024-04-05 | セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー | 高分子薬剤化合物の持続放出用の埋め込み型デバイス |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618531A (en) * | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
| US5212082A (en) * | 1991-03-13 | 1993-05-18 | New York University | Genetically modified tyrosine hydroxylase and uses thereof |
| WO1993014790A1 (en) * | 1992-01-23 | 1993-08-05 | New York University | A method for transplanting cells into the brain and therapeutic uses therefor |
| DE69329556D1 (de) * | 1993-04-30 | 2000-11-16 | Photogenesis Inc | Transplantation des retinalen pigmentepithels |
| ES2169128T3 (es) * | 1994-04-13 | 2002-07-01 | Res Corp Technologies Inc | Procedimientos para el tratamiento de enfermedades utilizando celulas de sertoli y aloinjertos o xenoinjertos. |
| US5759536A (en) * | 1994-05-27 | 1998-06-02 | University Technology Corporation | Use of fas ligand to supress T-lymphocyte-mediated immune responses |
-
1998
- 1998-12-31 WO PCT/US1998/027730 patent/WO1999034834A1/en not_active Ceased
- 1998-12-31 CA CA002317115A patent/CA2317115A1/en not_active Abandoned
- 1998-12-31 AU AU20191/99A patent/AU759273B2/en not_active Ceased
- 1998-12-31 KR KR1020007007392A patent/KR20010033834A/ko not_active Ceased
- 1998-12-31 NZ NZ505459A patent/NZ505459A/en unknown
- 1998-12-31 EP EP98964988A patent/EP1044024A1/en not_active Withdrawn
- 1998-12-31 JP JP2000527281A patent/JP2002500202A/ja active Pending
-
2006
- 2006-02-27 US US11/363,911 patent/US20060147437A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002500202A5 (enExample) | ||
| CA2323073A1 (en) | Uses for human non-autologous mesenchymal stem cells | |
| Palladino Jr et al. | Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. | |
| JP5260272B2 (ja) | 混合細胞遺伝子治療 | |
| Ohlsson et al. | Growth hormone induces multiplication of the slowly cycling germinal cells of the rat tibial growth plate. | |
| JP3884474B2 (ja) | 免疫増強治療のための薬学的組成物 | |
| EP1699915B1 (de) | Verwendung des erythropoietins zur regeneration von lebergewebe | |
| AU2001281800B2 (en) | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells | |
| US6093393A (en) | Methods for preparing and using clonogenic fibroblasts and transfected clonogenic fibroblasts | |
| AU2001281800A1 (en) | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells | |
| EP1972684A1 (en) | Medium for culturing autologous human progenitor stem cells and applications | |
| KR100572217B1 (ko) | 생접착성 유도 체세포치료 | |
| JP2004500437A (ja) | 可動化活性を有する調製物 | |
| JP5102773B2 (ja) | 幹細胞のホーミングおよび生着を改善する方法 | |
| JP4237265B2 (ja) | 膵臓およびその他の細胞の刺激、培養および保存 | |
| HUP0002913A2 (hu) | Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára | |
| JP2008031179A (ja) | β−インターフェロンを使用して再狭窄を治療する方法 | |
| JPH03502922A (ja) | インターロイキン‐１蛋白質を含む局所創傷治療用製剤 | |
| Gifford et al. | Introduction to TNF and related lymphokines | |
| CN101444538B (zh) | 大肠杆菌及其基因工程菌在制备抗肝癌实体瘤药物中的应用 | |
| Fujiwara et al. | Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet | |
| JP2006518604A5 (enExample) | ||
| Eggermont et al. | In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models | |
| EP0116085B1 (en) | Interferon and interferon inducers combined with tobacco products | |
| JPS6193130A (ja) | 低投与量にてヒトの各種病気を系統的に処置するためのγ‐インタフエロン含有剤 |